Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1139195 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| SRR29988889_1.fastq.gz | Fastqsanger.gz | |||
| SRR29988889_2.fastq.gz | Fastqsanger.gz | |||
| SRR29988890_1.fastq.gz | Fastqsanger.gz | |||
| SRR29988890_2.fastq.gz | Fastqsanger.gz | |||
| SRR29988891_1.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 32 |
Similar Datasets
Project description:Samples from fruit juice vesicle tissue from three lemon genotypes (Frost Lisbon, Faris "sour" and Faris "sweet") differing in fruit acidity were compared at two developmental timepoints (immature, mature). Faris lemon appears to be a graft chimera with the L2 layer derived from normal acid lemon and layer L1 from Millsweet limetta or a closely related genotype. Fruit of Faris sour and Faris sweet grew on different branches of the same tree, with sour fruit developing on branches with L1 and L2 from acid lemon. genotype: Faris sweet lemon - developmental stage: PO:0007009 FF.01 fruit size 30%,(3-replications); genotype: Faris sweet lemon - developmental stage: PO:0007050 FR.03 late stage of fruit ripening,(3-replications); genotype: Faris acid lemon - developmental stage: PO:0007009 FF.01 fruit size 30%,(3-replications); genotype: Faris acid lemon - developmental stage: PO:0007050 FR.03 late stage of fruit ripening,(3-replications); genotype: Frost Lisbon lemon - developmental stage: PO:0007009 FF.01 fruit size 30%,(3-replications); genotype: Frost Lisbon lemon - developmental stage: PO:0007050 FR.03 late stage of fruit ripening,(3-replications) PLEXdb (http://www.plexdb.org) has submitted this series at GEO on behalf of the original contributor, Mikeal L. Roose. The equivalent experiment is CT1 at PLEXdb.
2011-12-07 | E-GEOD-12804 | biostudies-arrayexpress
Project description:Samples from fruit juice vesicle tissue from three lemon genotypes (Frost Lisbon, Faris "sour" and Faris "sweet") differing in fruit acidity were compared at two developmental timepoints (immature, mature). Faris lemon appears to be a graft chimera with the L2 layer derived from normal acid lemon and layer L1 from Millsweet limetta or a closely related genotype. Fruit of Faris sour and Faris sweet grew on different branches of the same tree, with sour fruit developing on branches with L1 and L2 from acid lemon.
2011-12-07 | GSE12804 | GEO
Project description:The use of Biological Control Agents (BCAs) to cope diseases has received considerable attention owing to its high efficiency and environmental safety. The aim of our study was to investigate the potential role of the Pseudomonas mediterranea pre-treatments in the response of lemon [Citrus limon (L.) Burm. f.] against mal secco, this being a devastating citrus disease caused by the fungus Plenodomus tracheiphilus. RNAseq analysis revealed that the fungus induced a marked reprogramming of the transcriptome, but P. Mediterranea pre-treatments strongly reduced lemon leaf transcriptome modifications and limited the amount of the fungus DNA inside the plant tissue. Furthermore, P. mediterranea prevented the down regulation of the genes involved in the effector triggered immunity (ETI) and the deregulation of genes involved in the main phytohormone’s biosynthesis and perception. As far as we know, this work represents the first report on the analysis of P. tracheiphilus-lemon plant-BCA interaction at molecular level.
2023-09-30 | GSE227934 | GEO
Project description:We explore whether a low-energy diet intervention for Metabolic dysfunction-associated steatohepatitis (MASH) improves liver disease by means of modulating the gut microbiome. 16 individuals were given a low-energy diet (880 kcal, consisting of bars, soups, and shakes) for 12 weeks, followed by a stepped re-introduction to whole for an additional 12 weeks. Stool samples were obtained at 0, 12, and 24 weeks for microbiome analysis. Fecal microbiome were measured using 16S rRNA gene sequencing. Positive control (Zymo DNA standard D6305) and negative control (PBS extraction) were included in the sequencing. We found that low-energy diet improved MASH disease without lasting alterations to the gut microbiome.
2024-12-31 | E-MTAB-14061 | biostudies-arrayexpress
Project description:The goals of this study are to reveal the transcriptional and regulatory dynamics of the lncRNAs in response to CLas infection and provide a reference for a better understanding of the role of lncRNAs involved in citrus HLB regulation. For the purpose, we obtained RNA-seq-based differential expression profile of the leave midrib of CLas- and mock-inoculated rough lemon and sweet orange at week 0, 7, 17, and 34 following infections with three biological replicates in the greenhouse. Approximately 2,523 million paired-end reads from 48 sample libraries were produced using Illumina HiSeq 2000. we systematically identified lncRNAs from rough lemon and sweet orange at four different time points of a greenhouse experiment and characterized their genomic transcriptional and regulatory dynamics. We predicted their potential regulatory genes and functions and constructed a co-expression network. Our study provides precious information and expands the knowledge of citrus lncRNA against HLB disease.
2023-03-15 | GSE215306 | GEO
Project description:Deciphering the dietary immunomodulatory effects of a medicinal plant leaf extract (MPLE) obateined from sage (Salvia officinalis, Lamiaceae) and lemon verbena (Lippia citriodora, Verbenaceae) upon the gut-associated lymphoid tissue (GALT) of gilthead seabream (Sparus aurata).
2021-06-02 | GSE166558 | GEO
Project description:Pancreatic cancer is the 3rd most prevalent cause of cancer related deaths in United states alone, with over 55000 patients being diagnosed in 2019 alone and nearly as many succumbing to it. Late detection, lack of effective therapy and poor understanding of pancreatic cancer systemically contributes to its poor survival statistics. Obesity and high caloric intake linked co-morbidities like type 2 diabetes (T2D) have been attributed as being risk factors for a number of cancers including pancreatic cancer. Studies on gut microbiome has shown that lifestyle factors as well as diet has a huge effect on the microbial flora of the gut. Further, modulation of gut microbiome has been seen to contribute to effects of intensive insulin therapy in mice on high fat diet. In another study, abnormal gut microbiota was reported to contribute to development of diabetes in Db/Db mice. Recent studies indicate that microbiome and microbial dysbiosis plays a role in not only the onset of disease but also in its outcome. In colorectal cancer, Fusobacterium has been reported to promote therapy resistance. Certain intra-tumoral bacteria have also been shown to elicit chemo-resistance by metabolizing anti-cancerous agents. In pancreatic cancer, studies on altered gut microbiome have been relatively recent. Microbial dysbiosis has been observed to be associated with pancreatic tumor progression. Modulation of microbiome has been shown to affect response to anti-PD1 therapy in this disease as well. However, most of the studies in pancreatic cancer and microbiome have remained focused om immune modulation. In the current study, we observed that in a T2D mouse model, the microbiome changed significantly as the hyperglycemia developed in these animals. Our results further showed that, tumors implanted in the T2D mice responded poorly to Gemcitabine/Paclitaxel (Gem/Pac) standard of care compared to those in the control group. A metabolomic reconstruction of the WGS of the gut microbiota further revealed that an enrichment of bacterial population involved in drug metabolism in the T2D group.
2020-11-30 | E-MTAB-8739 | biostudies-arrayexpress